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The bornavirus-derived human 
protein EBLN1 promotes efficient 
cell cycle transit, microtubule 
organisation and genome stability
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Anna E. Howard1, Ryan D. Beveridge1, Sarah Maslen2, J. Mark Skehel2 & Spencer J. Collis1
It was recently discovered that vertebrate genomes contain multiple endogenised nucleotide 
sequences derived from the non-retroviral RNA bornavirus. Strikingly, some of these elements have 
been evolutionary maintained as open reading frames in host genomes for over 40 million years, 
suggesting that some endogenised bornavirus-derived elements (EBL) might encode functional 
proteins. EBLN1 is one such element established through endogenisation of the bornavirus N gene 
(BDV N). Here, we functionally characterise human EBLN1 as a novel regulator of genome stability. 
Cells depleted of human EBLN1 accumulate DNA damage both under non-stressed conditions and 
following exogenously induced DNA damage. EBLN1-depleted cells also exhibit cell cycle abnormalities 
and defects in microtubule organisation as well as premature centrosome splitting, which we attribute 
in part, to improper localisation of the nuclear envelope protein TPR. Our data therefore reveal that 
human EBLN1 possesses important cellular functions within human cells, and suggest that other EBLs 
present within vertebrate genomes may also possess important cellular functions.
All viruses interact with cellular components of the host’s cells to facilitate their replication and infection cycles, 
and it has long been known that in addition to acquiring genes from their hosts, many retroviruses are capable 
of depositing endogenous viral elements into host genomes1–3. Over millions of years of viral infection, such 
integration events can accumulate, accounting for a significant proportion of the host organism’s genome1,2. 
Furthermore, during host evolution, endogenised retroviral elements can develop new functions within host cells. 
Although this is often associated with a role in inhibiting future viral infection4,5, some endogenised viral-derived 
elements can develop fundamental biological functions e.g. the essential role in mammalian placenta formation 
for the retroviral envelope gene-derived syncytin protein6,7.
Endogenisation of non-retroviral derived elements had not been observed in mammals until the recent dis-
covery of endogenous bornavirus elements (EBLs) in multiple vertebrate species, including humans8–12. These 
studies also revealed that endogenous bornavirus integration events have occurred independently in many dif-
ferent species on multiple occasions, and have been maintained within the host’s genome for over 40 million 
years8,10,12,13. Intriguingly, some human EBLs contain potential protein encoding open reading frames and are 
detected in expressed sequence tag databases8,10. This discovery therefore raised the possibility that some EBLs 
may encode proteins that have developed fundamental biological roles within the host cell.
We recently carried out a human genome-wide siRNA-based screen to identify novel regulators of genome stabil-
ity14–17. As part of our on-going analyses of candidates identified in this screen, the uncharacterised putative human 
gene LOC340900 was identified as a positive hit and therefore a potential novel genome stability factor. Following the 
discovery of EBLs in the human genome8,10, LOC340900 was subsequently renamed human EBLN1 as an EBL derived 
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from the bornavirus N element. As no known biological function for human EBLN1, or indeed any endogenous borna-
virus derived element had been determined, we carried out functional characterisation of human EBLN1.
Here we show that human EBLN1 facilitates a cell cycle transit and prevents the accumulation of both endog-
enous DNA damage and exogenously induced DNA damage. We also show that human EBLN1 is required for 
microtubule organisation and for preventing premature centrosome splitting, which we attribute, in part, to 
improper localisation of the nuclear envelope protein TPR. Our findings therefore demonstrate that akin to some 
retroviral-derived integrated elements, the evolutionary conserved endogenised bornavirus element EBLN1 has 
developed a functional role within human cells, and raises the possibility that other EBLs may have acquired 
biological functions within the host cell.
Results
Human EBLN1-depleted cells accumulate DNA damage. We recently carried out a human genome-
wide siRNA screen in HCT116 colorectal cancer cells to identify novel regulators of genome stability, employ-
ing increased γ H2AX immunofluorescent foci as an established cellular marker of DNA damage14–16. Using 
this approach, human EBLN1 (originally designated LOC340900) was identified as a strong positive candidate 
(z-score = 1.93), which we subsequently validated in both HeLa and MRC5A cells using the same siRNA pool 
used in the HCT116-based screen (Fig. 1A). These findings are consistent with the identification of LOC340900 
as a positive hit in a similar γ H2AX-based siRNA screen carried out in HeLa cells18, and are comparable with 
z-scores within our screen of well-established DNA damage response, cell cycle checkpoint and genome stabil-
ity factors such as CDC25A (2.15), CLSPN (2.05), RPA2 (2.02), Cyclin E (1.99), RFC1 (1.98) and WRN (1.95) 
amongst others. We next deconvolved the siRNA pool into 4 individual siRNA targeting EBLN1. All four EBLN1 
targeted siRNA gave increased DNA damage, from which, two individual EBLN1-directed siRNAs that gave the 
most robust depletion of EBLN1 and led to comparable increases in γ H2AX foci were selected to carry out the 
further functional characterisation of EBLN1 (Fig. 1B and Supplementary Figure S1A). In addition to a marked 
increase in γ H2AX foci, depletion of EBLN1 by either siRNA also resulted in increased 53BP1 foci (Fig. 1C); an 
established cellular marker of DNA double-strand breaks (DSBs). Consistent with these data, EBLN1-depleted 
cells showed a marked increased phosphorylation of ATM kinase on serine 1981 (Fig. 1D), an activating event in 
response to DNA damage. Finally, to confirm that these cellular markers are due to a physical increase in DNA 
breaks within EBLN1-depleted cells, we carried out COMET assays to directly visualise DNA breaks. Compared 
to control siRNA-treated cells, EBLN1-depleted cells exhibited an approximately 2-fold increase in the number 
of DNA breaks (Fig. 1E), which is consistent with the increased numbers of γ H2AX, 53BP1 and pATM foci, and 
comparable with the z-score of 1.93 obtained from the original siRNA-based γ H2AX screen.
Given that these findings, we sought to determine if EBLN1-depleted cells responded efficiently to exog-
enously induced DNA damage. Ionising radiation (IR) treated EBLN1-depleted cells exhibited a comparable 
DNA damage response signalling compared with control siRNA-transfected cells, as evidenced by the initial 
phosphorylation induction of the DNA damage signalling kinase ATM (Fig. 2A). However, unlike control 
siRNA-transfected cells, a high level of activated ATM was still present in EBLN1-depleted cells 24 hours post-IR 
(Fig. 2A), indicative of unresolved DNA lesions and/or persistent checkpoint activation. Consistent with this 
notion, EBLN1-depleted cells also exhibited increased amounts of γ H2AX and 53BP1 foci compared with control 
siRNA-transfected cells at late time points following IR (Fig. 2B,C respectively), exhibited increased IR sensitivity 
(Fig. 2D and Supplementary Figure S1B), post-IR induced G2/M delay, and a heightened amount of micronuclei 
compared with cells transfected with control non-targeting siRNA (Fig. 2E,F respectively). Collectively, these data 
suggested that DNA damage accumulates in EBLN1-depleted cells through an inability to appropriate resolve 
DNA lesions.
EBLN1-depleted cells exhibit cell cycle abnormalities. The heightened DNA damage in 
EBLN1-depleted cells, and the established links between DNA damage response and the cell cycle promoted us 
to determine if depletion of EBLN1 had any deleterious effects on cell cycle progression. Propidium iodide DNA 
staining in conjunction with FACS-based analyses was used to generate quantitative cell cycle profiles in control 
and EBLN1 siRNA-transfected cell populations. Depletion of EBLN1 gave a modest but consistent increase in the 
number of cells residing in the G2/M phase of the cell cycle (Fig. 3A and Supplementary Figure S1C), which is 
consistent with recent findings following knockdown of human EBLN1 in an oligodendroglia cell line19. To dis-
seminate this population further, we assessed G2 and M phase populations in control and EBLN1 siRNA-treated 
cells using Cyclin B1 and phosphorylated histone H3 on Ser10 (pH3 Ser10) respectively. Compared to con-
trol siRNA-transfected cells, EBLN1-depleted cells exhibited increased populations of Cyclin B1 positive and 
decreased populations of pH3 Ser10 positive cells (Fig. 3A and Supplementary Figure S1D). In keeping with 
theses findings, we also observed an increased number of mitotic cells in EBLN1-depleted cell populations 
(Supplementary Figure S1E), suggesting that transit through mitosis might be perturbed in EBLN1-depleted cells.
We therefore enriched siRNA-transfected cells for early mitotic populations using nocodazole and analysed 
cell cycle transit using PI, Cyclin B1 and pH3 Ser10 levels following nocodazole removal. Compared with con-
trol siRNA treated cells, EBLN1-depleted cells exhibited an initial increase in both the G2/M population and 
Cyclin B1 levels (Fig. 3B), suggesting either an inefficient release from nocodazole block, or an accumulation of 
late G2/early mitotic cells from cell populations that were initially arrested during the nocodazole treatment. As 
cells progressed through mitosis and into the next cell cycle, EBLN1-depleted cells exhibited a comparable rate 
in the reduction of Cyclin B1 levels to that observed in control siRNA-transfected cells (Fig. 3B). However, they 
consistently consisted of more Cyclin B1 positive cells at each time point post-nocodazole release compared 
with control siRNA-treated cells (Fig. 3B). In contrast, pH3 ser10 levels were always lower in EBLN1-depleted 
cells in both nocodazole-blocked cells and following resumption of cell cycle transit (Fig. 3B). These data there-
fore prompted us to study the mitotic transit of EBLN1-depleted cells in more detail by direct visualisation of 
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cells using immunofluorescence detection of DNA (DAPI), pH3 ser10 and α -tubulin to assess chromosome 
condensation and separation as cells progressed through mitosis. Compared with control siRNA transfected 
cells, EBLN1-depleted cells exhibited a greater proportion of cells in late stages of mitosis such as telophase 
and cytokinesis (Fig. 3C), which is consistent with an overall increase in mitotic bodies observed in nocoda-
zole blocked/released EBLN1-depleted cells (Supplementary Figures S1F), and a reduced growth rate in cells 
depleted of EBLN1 (Supplementary Figure S1G). To determine if these cell cycle abnormalities contributed to 
the increased DNA damage in EBLN1-depleted cells, or vice versa, we carried cell cycle synchronisation/release 
time course experiments. As observed in asynchronous cell populations, G0/G1 enriched, as well as post-release 
EBLN1-depleted cells exhibited increased amounts of DNA damage compared with control siRNA treated cells 
(Fig. 3D). Interestingly, unlike control siRNA treated cells that quickly re-entered cell cycle following release 
from serum starvation, EBLN1-depleted cells exhibited a severe delay in re-entering the cell cycle, which may be 
due to the higher amounts of DNA damage prevalent within these cells (Fig. 3D). Collectively, these data reveal 
that EBLN1-deficient cells exhibit cell cycle transit defects under normal growth conditions and in response to 
exogenously-induced cell cycle pausing.
Figure 1. EBLN1-depleted cells accumulate DNA damage. (A) Left and middle panels show representative 
immunofluorescence images of γ H2AX foci in HeLa and MRC5A cells respectively, with the right panel 
showing quantification of γ H2AX foci. Data shown represents the mean from at least three independent 
experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells). (B) Upper panel 
shows a representative western blot from HeLa cells demonstrating siRNA-mediated knockdown of EBLN1 
with two individual siRNA. Additional examples of efficient EBLN1 depletion using these two siRNA are shown 
in Supplementary Figure S1A. Bottom panel shows representative γ H2AX foci in control and individual EBLN 
siRNA-transfected HeLa cells, with the graph on right showing quantification of γ H2AX foci. Data shown 
represents the mean from at least three independent experiments with associated SEMs (**p ≤ 0.01 compared to 
control siRNA cells). (C) Left panel shows representative immunofluorescence staining of 53BP1 foci in control 
and EBLN1-transfecetd HeLa cells. Graph on right shows mean percentage of 53BP1 positive cells. Data shown 
represents the mean from at least three independent experiments with associated SEMs (**p ≤ 0.01 compared to 
control siRNA cells). (D) Same as (C), except for pATM (Ser1981) foci in siRNA-transfected cells. Data shown 
represents the mean from at least three independent experiments with associated SEMs (*p ≤ 0.05 compared to 
control siRNA cells). (E) Upper panel shows representative images of COMETs in control and EBLN1 siRNA-
transfected HeLa cells. Lower panels show quantification of mean percentage DNA in COMET tails and mean 
COMET tail moment. Data shown represents the mean from at least three independent experiments with 
associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells).
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EBLN1-depleted cells exhibit microtubule and centrosomal defects. Microtubules are critical for 
regulating cell growth as well as cell division processes through association with centrosomes, which are the main 
microtubule organising centres. As such, defects in microtubule organisation and centrosome number/duplication 
processes can lead to genome instability20. Therefore, given the increased genome instability and cell cycle defects 
observed in EBLN1-depleted cells, we sought to determine if EBLN1 is important for microtubule architecture. As 
previously described14,21, interphase U2OS cells transfected with control siRNA displayed an organised radial array 
of microtubules emanating from the centrosome (Fig. 4A). However, depletion of EBLN1 led to a marked loss of 
microtubule organisation (Fig. 4A), indicating that EBLN1 is important for maintaining a stable microtubule array. 
This is consistent with our findings that GFP-tagged EBLN1 resides mainly within the cytoplasm, likely due to the 
lack of the nuclear localisation sequences found in BDV N10,22, and is occasionally localised to microtubule struc-
tures (Supplementary Figure S1H), although this could be partly due to trafficking within the cell.
Figure 2. EBLN1-depleted cells fail to adequately repair exogenously induced DNA damage. (A) Left panel 
shows representative immunofluorescence images for phosphorylated ATM (pATM Ser1981) in HeLa cells 
transfected with either control of two individual EBLN1 siRNA at the indicated times post 3Gy IR. The graph 
on the right shows mean percentage of pATM foci positive cells in control and EBLN1 siRNA transfected cells. 
Data shown represents the mean from at least three independent experiments with associated SEMs (**p ≤ 0.01 
compared to control siRNA cells). (B) Same as (A), but for γ H2AX positive cells. Data shown represents the 
mean from at least three independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared 
to control siRNA cells). (C) Same as (B), but for 53BP1 foci positive cells. Data shown represents the mean 
from at least three independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to 
control siRNA cells). (D) Clonogenic survival curves for control and EBLN1 siRNA-transfected HeLa cells 
treated with the indicated doses of IR. Data shown represents the mean surviving fractions with their respective 
SEMs calculated from at least three independent experiments. Comparable data was obtained in MRC5A cells 
(Supplementary Figure S1B). (E) FACS-based quantification (PI staining) of G2/M cells in control and EBLN1 
siRNA-transfected HeLa cell populations at the indicated times post 3Gy IR. Data shown represents the mean 
from at least three independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to 
control siRNA cells). (F) Quantification of micronuclei in HeLa cells, as assessed by DAPI immunofluorescence 
staining, forty-eight hours post-transfection with either control or EBLN1 siRNA. Data shown represents the 
mean from at least three independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to 
control siRNA cells).
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We next assessed if microtubule organisation during regrowth was affected in EBLN1-depleted cells following 
rapid depolymerisation by treatment with ice14,21. Unlike control siRNA-transfected cells that rapidly regrew an 
organised microtubule network following release from ice treatments (Fig. 4B), cells depleted of EBLN1 exhibited 
an approximate 50% reduction in the proportion of cells exhibiting an organised microtubule array at compa-
rable time points (Fig. 4B). Given that both abnormal centrosome numbers as well as centrosomal separation 
defects can give rise to microtubule abnormalities and genome instability20,23,24, and the microtubule defects and 
heightened genome instability present associated with EBLN1 deficiency, we next assessed if centrosomal defects 
were evident in EBLN1-depleted cells. The most striking feature of EBLN1-depleted cells was a marked increase 
in centrosome splitting (Fig. 4C). This phenotype is unlikely to be a consequence of large changes to cell cycle 
positioning, as this is not evident in EBLN1-depleted cells (Fig. 3A and Supplementary Figure S1C), and is a 
much smaller distance to that associated with cells in G2 phases of the cell cycle25, suggesting that reduced levels 
of EBLN1 impact on microtubule organisation and regrowth.
Figure 3. Cell cycle abnormalities in EBLN1-depleted cells. (A) Left, middle and right panels show respective 
FACS-based quantification of G2/M cells (propidium iodide staining), Cyclin B1 and phosphorylated Histone 
H3 (Ser10) positively stained HeLa cells in asynchronous cell populations transfected with the indicated siRNA. 
Data shown represents the mean from at least three independent experiments with associated SEMs (*p ≤ 0.05 
and **p ≤ 0.01 compared to control siRNA cells). (B) Same as in (A), but for cell populations arrested with 
nocodazole and released back into the cell cycle and indicated markers quantified at the indicated time points 
post-nocodazole release. EBLN1 siRNA transfected cells exhibited a statistically significant difference compared 
with control siRNA-transfected cells (p < 0.05 for G2/M cells and p < 0.01 for cyclin B1 and pH3 positive cells). 
(C) Left panel shows representative immunofluorescence staining of DAPI, phosphorylated histone H3 (Ser10) 
and alpha tubulin to highlight specific mitotic phases that were scored in siRNA-transfected HeLa cells. Right 
panel shows quantification of these mitotic phases in control and EBLN1 siRNA-transfected cells 4 hours post-
nocodazole release. The percentage of mitotic cells as assessed by DAPI-stained mitotic bodies in asynchronous 
and in populations following 4 hours post-nocodazole release are shown in Supplementary Figures S1E 
and S1F respectively. Data shown represents the mean from at least three independent experiments with 
associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells). (D) Upper panel shows cell cycle 
distributions of RPE-1 cells transfected with either control or two independent EBLN1 siRNA at the indicated 
times following release from serum starvation. Middle panel shows representative immunofluorescence staining 
for γ H2AX for the indicated cell populations with the graph below showing the average number of γ H2AX 
positive cells within the siRNA-transfected populations at the indicated time points. Data shown is from two 
independent experiments with associated SEMs (**p ≤ 0.01 compared to control siRNA cells).
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EBLN1 interacts with TPR, but not with the Cyclin B1-CDK1 complex. Previous work has suggested 
that the bornavirus N gene (BDV N), from which human EBLN1 is derived, interacts with Cyclin B1-CDK1 com-
plex within mammalian cells, which may be important for viral infection and propagation26. Given the role of 
Cyclin B1-CDK1 in controlling mitotic transit and the cell cycle abnormalities observed in EBLN1-depleted cells, 
we hypothesised that EBLN1 may also be binding to the Cyclin B1-CDK1 complex to facilitate normal mitotic 
transit. However, immunoprecipitation of endogenous EBLN1 failed to detect any interaction with endogenous 
Cyclin B1 (Fig. 5A). Likewise, Cyclin B1 or CDK1 did not co-purify with FLAG-tagged EBLN1 following induced 
expression in stable cell lines (Fig. 5B,C respectively).
To identify potential interactors of human EBLN1 as a means to help elucidate a possible mechanistic role in 
cell division and microtubule organisation/re-growth processes, we carried out proteomic analyses of purified 
FLAG-EBLN1 complexes using a tetracycline inducible cell line system (Fig. 5D). Consistent with the cell division 
and microtubule organisation/re-growth phenotypes observed in EBLN1-depleted cells, several potential EBLN1 
integrators we identified have known biological roles in the organisation and regulation of microtubules e.g. TPR, 
FRYL, SYNE2, CEP250 and CEP170 (Fig. 5E). Of particular interest were TPR (Translocated Promoter Region) 
and FRYL (Furry Homolog-Like). TPR is a nuclear basket protein that regulates mRNA transport through 
nuclear pore complexes27, and has also been shown to promote efficient mitotic progression through the regula-
tion of mitotic spindles28. FRYL is the human homologue of the drosophila Furry protein that regulates the actin 
cytoskeleton29. Through a number of experimental approaches, we were unable to verify any interactions between 
Figure 4. EBLN1 deficiency leads to microtubule and centrosomal defects. (A) Left panel; representative 
immunofluorescence images for γ tubulin (centrosomes), α tubulin (microtubules) and merged images with 
DAPI (nucleus), in interphase U2OS cells transfected with either control or two individual EBLN1 siRNA. 
The white arrows on the α tubulin images highlight the position of the centrosome from which a microtubule 
array should emanate. Right panel; quantification of organised microtubule (MT) arrays in interphase U2OS 
cells treated with either control or EBLN1 siRNA as indicated. Data shown represents the mean from three 
independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells). 
(B) Upper panel shows representative merged immunofluorescence images for γ tubulin, α tubulin and DAPI at 
the indicated times points post release from ice treatment. The graph below shows mean percentage of control 
and EBLN1 siRNA transfected U2OS cells exhibiting an organised microtubule array. Data shown represents 
the mean from at least three independent experiments with associated SEMs (**p ≤ 0.01 compared to control 
siRNA cells). (C) Left panel shows representative merged immunofluorescence images for γ tubulin and DAPI 
in U2OS cells transfected with the indicated siRNA. The white arrows highlight the centrosomes that are shown 
in the enlarged image below. Right panel shows the mean percentage of cells exhibiting split centrosomes in 
control and EBLN1 siRNA transfected (> 2 microns apart). Data shown represents the mean from at least three 
independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells).
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ELBN1 and FRYL (data not shown). However, we were able to detect an interaction between GFP-tagged EBLN1 
and endogenous TPR (Fig. 5F), as well as a weak but reproducible interaction between endogenous EBLN1 and 
at least one isoform of endogenous TPR (Fig. 5G), suggesting that these two proteins may functionally interact 
within human cells.
Functional interplay between EBLN1 and TPRN. Given our interaction data, we next assessed if deple-
tion of EBLN1 could impact TPR function. Depletion of EBLN1 caused disruption to the nuclear envelope local-
isation of TPR (Fig. 6A and Supplementary Figure S1J), which was not a consequence of reduced TPR expression 
levels (Supplementary Figure S1I). Given this finding, and that TPR has been previously shown to regulate 
microtubules28, we reasoned that the microtubule defects observed in EBLN1-depleted cells could be a conse-
quence of disrupted TPR function due to its mis-localisation. We therefore assessed microtubule organisation and 
Figure 5. EBLN1 does not interact with the Cyclin B1-CDK1 complex, but does interact with TPR. 
(A) Immunoprecipitation of endogenous EBLN1 from HeLa cells probed with either EBLN1 or Cyclin 
B1 antibodies. Agarose beads incubated with cell extracts and IgG was used as a negative control for non-
specific protein binding. Black arrow indicates FLAG-tagged EBLN1 band. (B) Immunoprecipitation (IP) of 
endogenous Cyclin B1 from asynchronous (upper panel) or mitotic (lower panel) FLAG-EBLN1 expressing 
HeLa cells probed with the indicated antibodies. The minus tetracycline (− Tet) samples (uninduced expression 
of FLAG-EBLN1) serve as negative controls for non-specific protein binding. (C) Immunoprecipitation of 
FLAG-EBLN1 from tetracycline-inducible HeLa cells probed with the indicated antibodies. Minus tetracycline 
samples serve as negative controls for non-specific protein binding. (D) Upper panel shows EBLN1 and FLAG 
western blots of eluates from FLAG-EBLN1 expressing tet-inducible HeLa cells. Lower panel shows a SYPRO 
Ruby stained polyacrylamide gel of FLAG eluates shown in the upper panel. Black arrow indicates FLAG-tagged 
EBLN1 band. (E) Table showing some of the most prevalent proteins co-immunoprecipitating with FLAG-
EBLN1 as determined by proteomic analyses of the eluates shown in (E). The number of unique peptides for 
each protein is shown for both uninduced and induced (− Tet and + Tet) samples to highlight enrichment in 
FLAG-EBLN1 eluates (+ Tet samples), along with the respective peptide coverage for each protein identified. 
(F) Indicated western blots on inputs (left panel), GFP immunoprecipitations and TPR immunoprecipitations 
(right panels) in stable tetracycline-inducible GFP-EBLN1 expressing HeLa cell lines. Arrows highlight 
GFP-EBLN1 band in each IP. Note that a longer exposure is shown for the TPR IPs compared with the GFP 
IPs. (G) TPR western blots of immunoprecipitated endogenous TPR from HeLa cells transfected with the 
indicated siRNA. Arrows highlight TPR isoforms (upper panel) and TPR-specific band in EBLN1 IPs (lower 
panel), which are reduced in cells transfected with TPR siRNA. Note that the TPR antibody is not capable of 
recognising endogenous TPR in the input lanes, only purified TPR in the IP lanes.
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centriolar distance in TPR-depleted cells. Similar to our findings for EBLN1-depleted cells, knockdown of TPR by 
two independent siRNA led to disrupted microtubule organisation in both interphase cells and during regrowth 
following acute disruption (Fig. 6B). Furthermore, depletion of TPR led to premature centrosome splitting phe-
notype, which was comparable to that observed in EBLN1-depleted cells (Fig. 6C). Finally, we determined that 
cells depleted of TPR accumulate DNA damage in a similar manner to that observed in EBLN1-depleted cells 
(Fig. 6D). This is in keeping with the fact that TPR was identified as a positive hit in both our γ H2AX screen 
(z-score of 1.8), and in a comparable screen carried out by the Cimprich laboratory18. Collectively these data 
provide compelling evidence that human EBLN1 has a biological function within human cells to facilitate TPR 
localisation at the nuclear envelope, promote a stable microtubule array and suppression of DNA damage.
Discussion
Endogenisation of viral genes into the genome of the host organism can give rise to retained viral-derived 
protein-encoding elements that possess advantageous biological functions1–3. Such biologically active roles of 
Figure 6. Functional interplay between EBLN1 and TPR. (A) Representative immunofluorescence images 
showing endogenous TPR staining in interphase U2OS cells transfected with the indicated siRNA. Additional 
examples are given in Supplementary Figure S1I. (B) Upper panel; representative immunofluorescence images 
of microtubule organisation (α tubulin staining; green, γ tubulin; red and DAPI; blue) in interphase U2OS cells 
treated with either control or TPR siRNA as indicated. White arrows indicate the centrosomes (microtubule 
organising centres) that are shown enlarged in the inset images. Lower panel; quantification of organised 
microtubule (MT) arrays in interphase U2OS cells treated with either control or TPR siRNA. Data shown 
represents the mean from three independent experiments with associated SEMs (*p ≤ 0.05 and **p ≤ 0.01 
compared to control siRNA cells). (C) Left panel; representative immunofluorescence images for centrosomes 
(γ tubulin; red) in control and TPR siRNA treated U2OS cells. White arrows indicate the centrosomes shown 
in the enlarged images below. Right panel; quantification of centrosome splitting defects observed in cells 
treated with either non-targeting control or TPR siRNA. Data shown represents the mean from at least three 
independent experiments with associated SEMs (**p ≤ 0.01 compared to control siRNA cells). (D) Left 
panel; representative immunofluorescent images of γ H2AX in control non-targeting and TPR siRNA treated 
U2OS cells, with graph on right showing average number of γ H2AX positive cells in each siRNA transfected 
population. Data shown represents the mean from at least three independent experiments with associated SEMs 
(*p ≤ 0.05 and **p ≤ 0.01 compared to control siRNA cells).
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endogenised viral elements are normally associated with reducing subsequent viral infection4,5. However, through 
evolutionary processes, endogenised viral elements can develop new and important biological functions within 
their original host’s genomes6,7. The recent discovery of 40 million year old endogenised bornavirus elements 
(EBLs) that comprised an ORF structure, and EST detection within the genomes of many vertebrates raised the 
possibility that some EBLs may have an active biological function8,10–13,30. Indeed, it has recently been demon-
strated that a ground squirrel EBLN is capable of inhibiting bornavirus replication and infection9, although a 
molecular understanding of how it may promote such biological functions remains unknown.
We show here that human EBLN1 is important for preventing the accumulation of endogenous DNA 
damage, as well as for the efficient repair of exogenously induced DNA damage. Furthermore, we reveal that 
EBLN1-depleted cells exhibit abnormal cell cycle progression (specifically in resolving the final stages of mitosis), 
which are likely a consequence of increased amounts of DNA damage along with microtubule and centrosomal 
splitting defects. This is particularly intriguing given the established links between centrosome dynamics and 
genome instability20,23,24, and that disruption to microtubules and/or premature centrosome splitting can affect 
chromosomal segregation dynamics31,32. In keeping with a model based on our data that these phenotypes are 
in part due to improper localisation and function of TPR in EBLN1-depleted cells; we show that TPR-depleted 
cells exhibit comparable microtubule and centrosomal defects to that observed in EBLN1-depleted cells, as 
well as increased amounts of DNA damage. Furthermore, it has previously been shown that disruption to TPR 
function through siRNA-mediated depletion causes chromosomal segregation defects28, and we show here that 
EBLN1-depleted cells exhibit increased numbers of micronuclei, a common consequence of mitotic division 
defects33, and a phenotype previously associated with deficiency in TPR28.
Intriguingly, TPR is one of only a few nuclear pore complex proteins that have been implicated in cancer 
development27,34. Given that genome instability is a defined hallmark of cancer cells19, our findings raise the 
possibility that disruption to EBLN1 function could play a potential role in the development and/or progres-
sion of human disease such as cancer. Analysis of the current Cancer Genome Atlas reveals that although no 
EBLN1 mutations have so far been identified in human tumours, a small percentage of tumour types exhibit 
EBLN1 amplification or deletion. This is interesting given our depletion data presented here, and more so by 
our attempts to rescue EBLN1-associated phenotypes using a combination of UTR-directed siRNA and ectopic 
expression of EBLN1, which in itself led to increased amounts of DNA damage (Supplementary Figure S2A). 
Interestingly, a similar phenotype was not observed in cells ectopically expressing BDV N, from which EBLN1 
is derived (Supplementary Figure S2B), which also failed to rescue cellular phenotypes associated with reduced 
human EBLN1 levels, thus suggesting that human EBLN1 has gained additional and important biological func-
tions within human cells during the many millions of years that it has resided within our genomes. In conclusion, 
our data represents the first detailed molecular and functional characterisation of a human endogenised borna-
virus element, and raises the possibility that other EBLs within vertebrate genomes may also possess important 
biological functions.
Materials and Methods
Cell culture. HeLa, MRC5VA, U2OS, RPE-1 and HEK293 and cells were maintained as adherent monolayer 
cultures in DMEM media containing 10% FBS and 1% penicillin/streptomycin at 37 °C in a humidified atmos-
phere of 5% CO2. HeLa Flp-in T-REx and HEK293 Flp-In T-REx cells (Invitrogen) were maintained in DMEM 
media containing 10% FBS and 1% penicillin/streptomycin, supplemented with 4 μ g/ml Blasticidin S (Melford) 
and 100 μ g/ml Zeocin (Invitrogen).
FACS analyses & cell cycle profiling. Cell populations were washed in PBS and fixed overnight in 70% 
ethanol at − 20 °C. Fixed samples were washed 3 times in PBS before treatment with 5 μ g of RNAse1 followed by 
the addition of 300 μ l of Propidium Iodide (50 μ g/ml) to each sample. FACS acquisition was carried out using a 
FACS-Calibur (Becton-Dickinson) and analysed by FlowJo (Tree Star, Inc). On average, 20,000 live cells were 
gated and quantified for each sample, with each condition replicated 2–3 times for each individual experiment. 
Statistically significant differences between cell populations were confirmed from at least 3 independent exper-
iments using a 2-tailed t-test, assuming equal variances. For nocodazole block/release experiments, cells were 
treated with 100 ng/ml for 16 hours and synchronisation confirmed by FACS analyses. For release experiments, 
nocodazole-containing media was removed, cells washed in PBS and fresh pre-warmed media added. Circa 
60,000 RPE-1 cells were seeded into one well of a 6 well plate per sample (on cover slips for immunofluorescence) 
and supplemented with growth media. To arrest the cells in G1/G0, the normal growth media was replaced 
with serum-free media and transfected with 0.5 μ M siRNA per sample, which then remained serum starved for 
~60 hrs. Synchronised serum-starved cell populations were then released into to growth media with the first 
sample was harvested 10 hours post release and then every 2 hours thereafter.
EBLN1 siRNA depletion. Briefly, 4 μ l Dharmafect 1 was mixed with 50 μ M siRNA and 1.2 × 104 cells were 
seeded into one well of a 6-well plate and transfected. This ratio was scaled appropriately depending on cell num-
ber and the surface area utilised. Cells were harvested at either 48 or 72 hours post treatment. siRNA sequences 
(Dharmacon On Target Plus) were as follows (all 5′ to 3′ ): Control siRNA: UAAUGUAUUGGAACGCAUA, 
EBLN1 siRNA 1: CCGCUGUUGUGUUGGAGAU, EBLN1 siRNA 2: UAGCUAUAAUGCAGGGCCA, EBLN1 
UTR: ACGUGAACUAAUCCUUAUAUU, TPR siRNA 1: GAAGAAGUGCGUAAGAAUA and TPR siRNA 2: 
UCAGUUGACUCCAGGAAUA.
Stable cell line production. Full-length EBLN1 was cloned from genomic DNA from HeLa cells 
and BDV N was cloned from a pCDFDuet-1 plasmid containing full-length BDV N. Each gene was cloned 
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into the Gateway entry vector pDONR221 (Life Technologies) following a PCR reaction with the following 
primer sets; EBLN1_F: GGGGACAAGTTTGTACAAAAAAGCAGGCTTGTCCCGCCCAAGAAACAAC 
and EBLN1_R:GGGGACCACTTTGTACAAGAAAGCTGGGTTTATTCAAATCCCGAAATCCC or BDV 
N_F: CTTTATGCGACTCCTGATTAGG and BDV N_R: CGGCCGATATCCAATTGAGAT. Purified 
pDONR221-EBLN1 and pDONR221-BDV N were independently mixed with LR clonase and either 
FLAG-pDEST/FRT/TO or GFP-pDEST/FRT/TO to generate FLAG- or GFP-tagged tetracycline inducible stable 
HeLa and HEK293 cell lines as previously described35. All plasmids were fully sequence verified using a range of 
external and internal sequencing primers.
Cell lysis and western blotting. Cell lysates were prepared by solubilising cell populations on ice for 
20 minutes in lysis buffer; 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM DTT and 1 mM EDTA 
supplemented with 50 U/μ l benzonase (Novagen), protease and phosphatase inhibitors (Sigma). Cleared lysates 
were produced by centrifugation of the resulting samples at 16,000 × g for 15 min at 4 °C. Gel electrophoresis 
was performed using the NuPAGE system (Invitrogen). Briefly, samples were resolved on 4–12% Bis-Tris gels 
in MOPS buffer, transferred to a PVDF membrane which was then probed for the protein of interest using anti-
bodies diluted in TBS containing 5% Marvel and 0.1% Tween-20 (Sigma). Antibodies used were: alpha-Tubulin 
(Abcam ab7792, 1:1000), pATM (ab36810), β -actin (Abcam; ab8226), Cyclin B1 (Cell Signaling; mAb4135), 
EBLN1 (in-house synthesis and purification of a rabbit polyclonal antibody through Sheaf Innovations/
BioServUK Ltd. using the peptide MSRPRNNPQTSSPQD), FLAG (Sigma; F3165), FLAG-HRP (Sigma; A8592), 
GFP (Abcam; ab290), anti-Histone H3 pSer10 (Cell Signaling; 9701), γ H2AX (Cell Signalling; 25775), securin 
(Abcam; ab79546), TPR (ab58344, ab170940 and ab70610), HRP-secondary antibodies (DAKO, FITC) and 
Alexa-Fluor antibodies (Invitrogen).
Immunoprecipitation and proteomic analyses. For purification of FLAG-tagged proteins, 1 mg of a 
whole-cell extract was incubated with 20 μ l of M2-anti FLAG beads (Sigma) for 16 hours at 4 °C. For immunopre-
cipitation using endogenous antibodies, 1–2 μ g of antibody was incubated with the sample for 1–2 hours before 
addition to 20 μ l of washed Protein A/G beads (Santa Cruz) and incubation for 16 hours at 4 °C. Beads were then 
pelleted and washed three times in 20x dry bead volumes of lysis buffer. The bound protein was eluted either by 
heating the beads at 95 °C for 5 min with 2x LDS buffer (Invitrogen) or by incubation with FLAG peptide (Sigma) 
according to manufacturer’s instructions. Inputs represent ~1/20th of the extract used for the immunoprecipita-
tion. For proteomic analyses, protein samples were reduced, alkylated and digested with trypsin, using the Janus 
liquid handling system (PerkinElmer, UK). The digests were subsequently analysed by LC-MS/MS on an LTQ 
Orbitrap XL mass spectrometer, (ThermoScientific, San Jose, USA). LC-MS/MS data were searched against a 
protein database (UniProt KB) using the Mascot search engine programme and all subsequent data were inter-
rogated manually.
Immunofluorescence. 1.2 × 103 cells were seeded onto 200 mm glass cover slips in 6 well plates and 
incubated for 24 hrs for the cells to adhere. Following appropriate siRNA treatments and/or drug treatments, 
cells were fixed in either ice-cold 100% methanol or 4% PFA for 10 minutes (depending on the antibody used). 
Coverslips were washed briefly in PBS and extracted with 3% BSA, 0.2% Triton-X100 dissolved in PBS for 30 min-
utes, followed by a further brief wash in PBS. Antibodies were diluted in PBS containing 1% BSA at optimised 
concentrations and a 100 μ l aliquot added to each cover slip for 1 hour. This was followed by 3 × 5 minutes washes 
in PBS. Secondary Alexa-Fluor antibodies (1:500) and DAPI (1 μ g/ml) were diluted in PBS containing 1% BSA 
and a 100 μ l aliquot added to each cover slip for 1 hour. This was followed by 3 × 5 minutes washes. Processed cov-
erslips were mounted onto glass slides with 10 μ l Shandon immuno-mount (Thermo). Microtubule array assays 
were carried out as previously described14. All immunofluorescence images were captured on a Nikon Eclipse 
T200 inverted microscope (Melville), equipped with a Hamamatsu Orca ER camera, a 200 W metal arc lamp 
(Prior Scientific,UK) and an 60x objective lens. Images were captured and analysed using Volocity 3.6.1 software 
(Improvision) and exported as tiff files. Scoring for each individual condition (siRNA, cell line, drug treatment 
etc.) within an experiment was carried out on at least 10 separate fields of view containing between 200–300 cells 
in total. Cells were scored positive for DDR foci if they contained > 5 discrete foci per nucleus and the mean per-
centage of positive cells from at least 3 independent experiments were then calculated and plotted along with their 
respective standard errors of the means (SEM). Statistically significant differences between cell populations was 
confirmed using a 2-tailed t-test, assuming equal variances and are presented on figures as *p ≤ 0.05, **p ≤ 0.01.
Quantitative PCR. RNA was extracted from cells using a Qiagen RNEasy Plus Kit and quantified on a 
Nanodrop spectrophotometer. Equal quantities of RNA (2 μ g) were then reverse transcribed using an Applied 
Biosystems High Capacity RNA- cDNA kit as per the manufacturer’s instructions. Resulting cDNAs were diluted 
as needed to carry out 10 μ l Taqman reactions in triplicate using an Applied Biosystems Taqman Gene Expression 
Master Mix and Applied Biosystems 7900HT Thermal cycler using the manufacturer’s recommended conditions 
and analysed, which were subsequently analysed using Applied Biosystems SDS 2.4 software to calculate respec-
tive Δ ct values and relative gene expression levels. Taqman probes used were GAPDH; Hs02758991_g1, EBLN1; 
Hs00908304_s1 and TPR; Hs00162918_m1.
COMET assays. Alkaline COMET assays were performed using the Trevigen kit system according to the 
manufacturers’ protocol. Briefly, cells were re-suspended at 1 × 105 per ml in low melting point agarose and trans-
ferred to the COMET slide. After setting, slides were incubated for 30 min in lysis solution, and then incubated 
in unwinding solution for 20 min. Slides were then electrophoresed at 21 volts for 30 min before rinsing twice 
in water and once in 70% ethanol. After drying, cells were stained with SYBR Green and visualised by fluores-
cence microscopy. COMET tail moments were analysed from at least 100 cells per condition using COMETScore 
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software and from at least 3 independent experiments. Statistically significant differences between cell popula-
tions were confirmed from at least 3 independent experiments using a 2-tailed t-test, assuming equal variances.
Cytotoxicity and clonogenic survival assays. For MTT cytotoxicity assays, cells were plated at a density 
of between 1000–2000 cells/well in 96-well plates (dependant on cell line used), and the following day transfected 
with appropriate siRNA, and drug added 2 days later at various concentrations. After 5 days of growth, MTT 
reagent was added to the cells at a final concentration of 3 mg/ml, and incubated at 37 °C for 3 hrs. The media was 
removed and replaced with 200 μ l DMSO to solubilise the formazan product, which was quantified by determin-
ing optical density at 540 nm using a spectrophotometric microtitre plate reader. Cytotoxicity was calculated for 
each treatment by normalisation to appropriate vehicle only controls for each set of transfectants. For clonogenic 
survival assays, 500–5000 cells were plated onto 100 mm dishes in triplicate 4 hour prior to treatment with ion-
ising radiation (IR) to allow cells to attach. When colonies could be observed in the control plates (10–14 days 
post-IR), cells were fixed and stained with methylene blue in methanol (4 g/L), and colonies consisting of more 
than 50 cells were subsequently scored. Surviving fractions (SF) were calculated based on the plating efficiency 
(fraction of colonies formed in untreated plates) for each cell population/treatment as; SF = (No. cells counted)/
(No. cells plated x plating efficiency).
References
1. Jern, P. & Coffin, J. M. Effects of retroviruses on host genome function. Annu Rev Genet 42, 709–732, doi: 10.1146/annurev.
genet.42.110807.091501 (2008).
2. Katzourakis, A. & Gifford, R. J. Endogenous viral elements in animal genomes. PLoS Genet 6, e1001191, doi: 10.1371/journal.
pgen.1001191 (2010).
3. Zhdanov, V. M. Integration of viral genomes. Nature 256, 471–473 (1975).
4. Malfavon-Borja, R. & Feschotte, C. Fighting Fire with Fire: Endogenous Retrovirus Envelopes as Restriction Factors. J Virol 89, 
4047–4050, doi: 10.1128/JVI.03653-14 (2015).
5. Aswad, A. & Katzourakis, A. Paleovirology and virally derived immunity. Trends Ecol Evol 27, 627–636, doi: 10.1016/j.
tree.2012.07.007 (2012).
6. Mi, S. et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 403, 785–789, doi: 
10.1038/35001608 (2000).
7. Dupressoir, A. et al. Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-
derived, envelope gene. Proc Natl Acad Sci USA 106, 12127–12132, doi: 10.1073/pnas.0902925106 (2009).
8. Belyi, V. A., Levine, A. J. & Skalka, A. M. Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/
marburgvirus sequences in vertebrate genomes. PLoS Pathog 6, e1001030, doi: 10.1371/journal.ppat.1001030 (2010).
9. Fujino, K., Horie, M., Honda, T., Merriman, D. K. & Tomonaga, K. Inhibition of Borna disease virus replication by an endogenous 
bornavirus-like element in the ground squirrel genome. Proc Natl Acad Sci USA 111, 13175–13180, doi: 10.1073/pnas.1407046111 
(2014).
10. Horie, M. et al. Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature 463, 84–87, doi: 10.1038/
nature08695 (2010).
11. Parrish, N. F. et al. piRNAs derived from ancient viral processed pseudogenes as transgenerational sequence-specific immune 
memory in mammals. RNA 21, 1691–1703, doi: 10.1261/rna.052092.115 (2015).
12. Sofuku, K., Parrish, N. F., Honda, T. & Tomonaga, K. Transcription Profiling Demonstrates Epigenetic Control of Non-retroviral 
RNA Virus-Derived Elements in the Human Genome. Cell Rep 12, 1548–1554, doi: 10.1016/j.celrep.2015.08.007 (2015).
13. Horie, M., Kobayashi, Y., Suzuki, Y. & Tomonaga, K. Comprehensive analysis of endogenous bornavirus-like elements in eukaryote 
genomes. Philos Trans R Soc Lond B Biol Sci 368, 20120499, doi: 10.1098/rstb.2012.0499 (2013).
14. Staples, C. J. et al. Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability. J Cell Sci 127, 
2910–2919, doi: 10.1242/jcs.147785 (2014).
15. Staples, C. J. et al. The centriolar satellite protein Cep131 is important for genome stability. J Cell Sci 125, 4770–4779, doi: 10.1242/
jcs.104059 (2012).
16. Barone, G. et al. Human CDK18 promotes replication stress signaling and genome stability. Nucleic Acids Res, Advance Access, July 
5, doi: 10.1093/nar/gkw1615, 10.1093/nar/gkw615 (2016).
17. Staples, C. J. et al. MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response. Cell Rep 16, 
2565–2575, doi: 10.1016/j.celrep.2016.07.087 (2016).
18. Paulsen, R. D. et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol 
Cell 35, 228–239, doi: 10.1016/j.molcel.2009.06.021 (2009).
19. He, P. et al. Knock-Down of Endogenous Bornavirus-Like Nucleoprotein 1 Inhibits Cell Growth and Induces Apoptosis in Human 
Oligodendroglia Cells. Int J Mol Sci 17, 435, doi: 10.3390/ijms17040435 (2016).
20. Nam, H. J., Naylor, R. M. & van Deursen, J. M. Centrosome dynamics as a source of chromosomal instability. Trends Cell Biol 25, 
65–73, doi: 10.1016/j.tcb.2014.10.002 (2015).
21. Dammermann, A. & Merdes, A. Assembly of centrosomal proteins and microtubule organization depends on PCM-1. J Cell Biol 
159, 255–266, doi: 10.1083/jcb.200204023 (2002).
22. Kobayashi, T. et al. Nuclear targeting activity associated with the amino terminal region of the Borna disease virus nucleoprotein. 
Virology 243, 188–197, doi: 10.1006/viro.1998.9049 (1998).
23. Nam, H. J. & van Deursen, J. M. Cyclin B2 and p53 control proper timing of centrosome separation. Nat Cell Biol 16, 538–549, doi: 
10.1038/ncb2952 (2014).
24. Zhang, Y. et al. USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis. J Clin Invest 122, 
4362–4374, doi: 10.1172/JCI63084 (2012).
25. Faragher, A. J. & Fry, A. M. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic 
spindles. Mol Biol Cell 14, 2876–2889, doi: 10.1091/mbc.E03-02-0108 (2003).
26. Planz, O. et al. Borna disease virus nucleoprotein interacts with the CDC2-cyclin B1 complex. J Virol 77, 11186–11192 (2003).
27. Snow, C. J. & Paschal, B. M. Roles of the nucleoporin Tpr in cancer and aging. Adv Exp Med Biol 773, 309–322, doi: 10.1007/978-1-
4899-8032-8_14 (2014).
28. Nakano, H., Funasaka, T., Hashizume, C. & Wong, R. W. Nucleoporin translocated promoter region (Tpr) associates with dynein 
complex, preventing chromosome lagging formation during mitosis. J Biol Chem 285, 10841–10849, doi: 10.1074/jbc.M110.105890 
(2010).
29. Nagai, T., Ikeda, M., Chiba, S., Kanno, S. & Mizuno, K. Furry promotes acetylation of microtubules in the mitotic spindle by 
inhibition of SIRT2 tubulin deacetylase. J Cell Sci 126, 4369–4380, doi: 10.1242/jcs.127209 (2013).
30. Horie, M. & Tomonaga, K. Non-retroviral fossils in vertebrate genomes. Viruses 3, 1836–1848, doi: 10.3390/v3101836 (2011).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:35548 | DOI: 10.1038/srep35548
31. Conroy, P. C. et al. C-NAP1 and rootletin restrain DNA damage-induced centriole splitting and facilitate ciliogenesis. Cell Cycle 11, 
3769–3778, doi: 10.4161/cc.21986 (2012).
32. Mardin, B. R. et al. EGF-induced centrosome separation promotes mitotic progression and cell survival. Dev Cell 25, 229–240, doi: 
10.1016/j.devcel.2013.03.012 (2013).
33. Zhang, C. Z. et al. Chromothripsis from DNA damage in micronuclei. Nature 522, 179–184, doi: 10.1038/nature14493 (2015).
34. Simon, D. N. & Rout, M. P. Cancer and the nuclear pore complex. Adv Exp Med Biol 773, 285–307, doi: 10.1007/978-1-4899-8032-
8_13 (2014).
35. Beveridge, R. D. et al. The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication 
stress signaling. Cell Cycle 13, 3450–3459, doi: 10.4161/15384101.2014.956529 (2014).
Acknowledgements
We thank Prof. Winfried Weissenhorn (Unit of Virus Host Cell Interactions, France) for kindly providing us with 
the pCDFDuet-1 plasmid containing full-length BDV N. We also thank Dr Patrick Eyers, Dr. Helen Bryant and 
Professor Mark Meuth for insightful discussions during this work. This work was funded by a Cancer Research 
UK (CR-UK) Senior Cancer Research Fellowship awarded to SJC (#C36435/A12102), which also supports KNM, 
AG and CJS. GB and RDB were funded respectively by a Yorkshire Cancer Research project grant (S312) and PhD 
studentship (S001PhD) awarded to SJC, with GB being additionally support by a Weston Park Hospital Cancer 
Charity project grant (CA146) awarded to SJC.
Author Contributions
S.J.C., K.N.M. and G.B. devised the experiments. K.N.M., G.B., A.G., C.J.S., A.E.H., R.D.B., S.M. and J.M.S. 
carried out the experiments. S.J.C. wrote the manuscript with additional help and contributions from the other 
co-authors.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Myers, K. N. et al. The bornavirus-derived human protein EBLN1 promotes efficient 
cell cycle transit, microtubule organisation and genome stability. Sci. Rep. 6, 35548; doi: 10.1038/srep35548 
(2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
	   1 
Supplementary Figure legends and Figures for: 
 
The bornavirus-derived human protein EBLN1 promotes efficient 
cell cycle transit, microtubule organisation and genome stability. 
Katie N. Myers1*, Giancarlo Barone1*, Anil Ganesh1, Christopher J. Staples1♯, 
Anna E. Howard1, Ryan D. Beveridge1, Sarah Maslen2, J. Mark Skehel2, & 
Spencer J. Collis1*. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   2 
Supplementary Figure S1.  
A: Representative western blots in U2OS (upper panel) and RPE-1 cells (lower 
panel) transfected with either control or two individual EBLN1-targetting siRNA. 
Actin blots serve as a loading control. B: Clonogenic survival curves for control 
and EBLN1 siRNA-transfected MRC5A cells treated with the indicated doses of 
IR. Data shown represents the mean surviving fractions with their respective 
SEMs calculated from at least three independent experiments. C: Left and right 
panels show FACS-based quantification (PI) of cell cycle phases respectively in 
HeLa or MRC5A cells transfected with the indicated siRNA. Data shown 
represents the mean from at least three independent experiments with associated 
SEMs (*p≤0.05 compared to control siRNA cells). D: Western blot showing 
reduced phosphorylated histone H3 (Ser10) in asynchronous EBLN1 siRNA-
transfected cells, which is complementary to the data shown in Figure 3B. E: 
Quantification of mitotic cells (DAPI stained bodies assess by 
immunofluorescence) in asynchronous cell populations. Data shown represents 
the mean from at least three independent experiments with associated SEMs 
(*p≤0.05 compared to control siRNA cells). F: Same as in (D), but in cell 
populations following 4 hours following release from an overnight nocodazole 
treatment. Note that data shown in Figures S1E and S1F are complementary to 
that shown in Figure 3C. Data shown represents the mean from at least three 
independent experiments with associated SEMs (*p≤0.05 compared to control 
siRNA cells). G: Growth curves (MTT) for cells treated with either control of 
EBLN1 siRNA assessed over the indicated time period. Data shown represents 
the mean surviving fractions with their respective SEMs calculated from at least 
three independent experiments. These data are consistent with recent findings of 
reduced growth rates following knockdown of human EBLN1 in an oligodendroglia 
cell line1. H: Representative immunofluorescence detection of GFP-tagged 
EBLN1 in tetracycline inducible expressing stable cell lines. The observed 
cyctoplasmic localisation of human EBLN1 is consistent with that observed in 
human oligodenroglioma cells transiently transfected with a plasmid expressing 
HA-tagged human EBLN12. I: Additional immunofluorescence images showing 
endogenous TPR staining in U2OS cells transfected with the indicated siRNA as 
shown in Figure 6A. J: Quantification of EBLN1 and TPR mRNA levels by RT-
PCR 48hrs post-transfection with the indicated siRNA. Percentage knockdown of 
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target mRNA (normalised to GAPDH levels) were calculated compared to non-
targeting control siRNA transfected cells, and data shown is the average from two 
independent experiments with their respective SEMs. 
 
 
Supplementary Figure S2.  
A: Upper panel; representative immunofluorescence images of γH2AX staining in 
tetracycline-inducible GFP-EBLN1 expressing cells as indicated. Lower panel; 
quantification of the percentage of cells exhibiting >10 γH2AX foci per cell in the 
indicated cell populations. Data shown represents the mean from at least three 
independent experiments with associated SEMs (**p≤0.01 compared to control 
siRNA cells). B: Left panel; representative western blot showing tetracycline-
inducible expression of GFP-tagged BDV N. Cells were treated with either control 
non-targeting siRNA or siRNA targeting human EBLN1 as indicated to show 
specificity towards human EBLN1. Right panel; quantification of the percentage of 
cells exhibiting >10 γH2AX foci per cell in the indicated cell populations. . Data 
shown represents the mean from at least three independent experiments with 
associated SEMs (**p≤0.01 compared to control siRNA cells). Note that the high 
background observed in the -Tet control siRNA treated cells can occasionally 
occur in these cells and has been previously reported3. 
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